Radioimmunotherapy with 90Y-Zevalin in mantle cell lymphoma patients.

被引：0
|
作者：
Sowa-Staszczak, A.
Hubalewska-Dydejczyk, A.
Jurczak, W.
Huszno, B.
Giza, A.
Wegrzyn, J.
Skotnicki, A.
机构：
[1] Jagiellonian Univ, Dept Endocrinol, Coll Med, Nucl Med Unit, Krakow, Poland
[2] Jagiellonian Univ, Dept Hematol, Coll Med, Krakow, Poland
[3] Jagiellonian Univ, Chair Hematol, Coll Med, Krakow, Poland
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2006年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S195 / S195
页数：1
相关论文
共 50 条
  • [41] Subsequent antilymphoma therapies are feasible after radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin®).
    Ansell, SM
    Schilder, RJ
    Pieslor, PC
    Gordon, LI
    Emmanouilides, C
    Czuczman, MS
    Wang, H
    Witzig, TE
    Saville, MW
    Molina, A
    BLOOD, 2003, 102 (11) : 308B - 308B
  • [42] Feasibility of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) radioimmunotherapy for non-Hodgkin's lymphoma in a patient with chronic renal failure.
    Spies, SM
    Gordon, LI
    Zimmer, AM
    Cutrera, P
    BLOOD, 2004, 104 (11) : 244B - 244B
  • [43] Evaluation of baseline body-weight dosing of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) radioimmunotherapy in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
    Wiseman, G
    Conti, P
    Vo, K
    Schilder, RJ
    Foster, P
    Gordon, LI
    Emmanouilides, C
    Silverman, D
    Witzig, TE
    Molina, A
    BLOOD, 2004, 104 (11) : 721A - 721A
  • [44] Radioimmunotherapy with 90Y-Zevalin in recurrent cb-cc-Non-Hodgkin-Lymphom (NHL) stage IVa with FDG PET therapy monitoring showing a rapid decrease of the glucose untilisation
    Sauter, B.
    Happel, C.
    Selkinski, I.
    Middendorp, M.
    Plastowez, W.
    Truong, P. N.
    Diener, J.
    Kranert, W. T.
    Gruenwald, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S352 - S352
  • [45] Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal antibody
    Wiseman, GA
    White, CA
    Witzig, TE
    Gordon, LI
    Emmanouilides, C
    Raubitschek, A
    Janakiraman, N
    Gutheil, J
    Schilder, RJ
    Spies, S
    Silverman, DHS
    Grillo-López, AJ
    CLINICAL CANCER RESEARCH, 1999, 5 (10) : 3281S - 3286S
  • [46] Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry
    Karin Hohloch
    Christine Windemuth-Kieselbach
    Pier Luigi Zinzani
    Roberto Cacchione
    Wojciech Jurczak
    C. Suh
    Lorenz Trümper
    Christian W. Scholz
    Annals of Hematology, 2020, 99 : 1073 - 1079
  • [47] A phase II trial of CHOP chemotherapy followed by Yttrium 90 (90Y) ibriturnomab tiuxetan (Zevalin®) for previously untreated elderly diffuse large B-Cell lymphoma (DLBCL) patients.
    Zinzani, Pier Luigi
    Tani, Monica
    Fanti, Stefano
    Stefoni, Vittorio
    Musuraca, Gerardo
    Castellucci, Paolo
    Marchi, Enrica
    Fina, Mariapaola
    Baccarani, Michele
    BLOOD, 2006, 108 (11) : 688A - 688A
  • [48] Testicular involvement in mantle cell lymphoma: An analysis of 16 patients.
    Alkhalili, Samer
    Manogna, Dharmini
    Safah, Hana
    Ellent, Elizabeth
    Beversdorf, Walter
    Arora, Ruby
    Saba, Nakhle S.
    LEUKEMIA RESEARCH REPORTS, 2023, 20
  • [49] Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry
    Hohloch, Karin
    Windemuth-Kieselbach, Christine
    Zinzani, Pier Luigi
    Cacchione, Roberto
    Jurczak, Wojciech
    Suh, C.
    Truemper, Lorenz
    Scholz, Christian W.
    ANNALS OF HEMATOLOGY, 2020, 99 (05) : 1073 - 1079
  • [50] 90Y-ibritumomab tiuxetan (Zevalin®) consolidation in non-Hodgkin's B lymphoma: severe haematological toxicity reported in two Mantle patients
    Pena, F. J.
    Crespo-Jara, A.
    Sureda, M.
    Redal, M. C.
    Garcia-Cases, F.
    Rebello, J.
    Fernandez, P. L.
    Evgenyeva, E.
    Brugarolas, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S149 - S149
12345